Tri Locum Partners LP Invests $38.98 Million in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Tri Locum Partners LP purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 369,004 shares of the medical equipment provider's stock, valued at approximately $38,978,000. Zimmer Biomet comprises 8.1% of Tri Locum Partners LP's investment portfolio, making the stock its 2nd biggest holding. Tri Locum Partners LP owned about 0.19% of Zimmer Biomet as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in ZBH. Stonebridge Financial Group LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter worth approximately $25,000. Kentucky Trust Co acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at $39,000. OFI Invest Asset Management acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at $40,000. SRS Capital Advisors Inc. raised its stake in shares of Zimmer Biomet by 146.9% in the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock valued at $51,000 after purchasing an additional 285 shares in the last quarter. Finally, Atala Financial Inc acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at $51,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

ZBH stock traded up $0.27 during trading hours on Wednesday, reaching $103.06. The stock had a trading volume of 1,399,563 shares, compared to its average volume of 1,667,028. The stock has a market capitalization of $20.39 billion, a PE ratio of 23.16, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock has a 50-day simple moving average of $105.76 and a 200 day simple moving average of $106.57. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $93.10 and a fifty-two week high of $123.96.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the company earned $2.20 earnings per share. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's dividend payout ratio is currently 21.57%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ZBH. Truist Financial reiterated a "hold" rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Royal Bank of Canada dropped their price objective on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Stifel Nicolaus increased their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research note on Thursday, January 23rd. Raymond James decreased their target price on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Finally, Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $124.15.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.95% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.